Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
暂无分享，去创建一个
L. Rubinstein | J. Doroshow | A. Chen | R. Parchment | S. Kummar | Biswajit Das | J. Ji | R. Piekarz | Li Chen | K. Do | R. Kinders | N. Takebe | G. Mugundu | Geraldine O’Sullivan Coyne | E. Sharon | L. Juwara | D. Wilsker | A. Mittra | H. Streicher | A. Naqash | Jennifer Zlott | Ting-Chia Chang | Ashley Bruns | Sarah B. Miller | G. O’Sullivan Coyne